70.83
price up icon1.48%   1.035
after-market アフターアワーズ: 69.51 -1.325 -1.87%
loading
前日終値:
$69.80
開ける:
$70.96
24時間の取引高:
1.32M
Relative Volume:
2.05
時価総額:
$4.50B
収益:
-
当期純損益:
$-159.39M
株価収益率:
-20.01
EPS:
-3.5401
ネットキャッシュフロー:
$-105.22M
1週間 パフォーマンス:
+3.26%
1か月 パフォーマンス:
+825.95%
6か月 パフォーマンス:
+1,101%
1年 パフォーマンス:
+498.77%
1日の値動き範囲:
Value
$69.58
$71.84
1週間の範囲:
Value
$65.67
$72.90
52週間の値動き範囲:
Value
$4.77
$72.90

Abivax Adr Stock (ABVX) Company Profile

Name
名前
Abivax Adr
Name
セクター
Healthcare (1166)
Name
電話
-
Name
住所
-
Name
職員
69
Name
Twitter
Name
次回の収益日
2025-06-02
Name
最新のSEC提出書
Name
ABVX's Discussions on Twitter

ABVX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ABVX
Abivax Adr
70.83 5.25B 0 -159.39M -105.22M -3.5401
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Abivax Adr Stock (ABVX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-23 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-03-20 開始されました Morgan Stanley Equal-Weight
2024-12-04 開始されました JMP Securities Mkt Outperform
2024-07-29 開始されました Laidlaw Buy
2024-05-20 開始されました BTIG Research Buy
2024-04-29 開始されました Guggenheim Buy
2024-04-29 開始されました Piper Sandler Overweight
2023-11-14 開始されました Leerink Partners Outperform
2023-11-14 開始されました Morgan Stanley Equal-Weight
すべてを表示

Abivax Adr (ABVX) 最新ニュース

pulisher
Jul 26, 2025

Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World

Jul 26, 2025
pulisher
Jul 26, 2025

Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World

Jul 26, 2025
pulisher
Jul 26, 2025

Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World

Jul 26, 2025
pulisher
Jul 25, 2025

Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World

Jul 25, 2025
pulisher
Jul 25, 2025

Abivax SA Stock Surges on Promising Drug Results - TipRanks

Jul 25, 2025
pulisher
Jul 24, 2025

Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Abivax ADR Shows Rising Price Performance With Jump To 99 RS Rating - Investor's Business Daily

Jul 24, 2025
pulisher
Jul 24, 2025

Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewswire Inc.

Jul 24, 2025
pulisher
Jul 23, 2025

Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily

Jul 23, 2025
pulisher
Jul 23, 2025

10 Best First Jobs for Aspiring CEOs - inkl

Jul 23, 2025
pulisher
Jul 23, 2025

Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com

Jul 23, 2025
pulisher
Jul 23, 2025

Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Harmony Gold Mining ADR Shows Market Leadership With Jump To 82 RS Rating - inkl

Jul 22, 2025
pulisher
Jul 21, 2025

Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World

Jul 21, 2025
pulisher
Jul 17, 2025

The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com

Jul 17, 2025
pulisher
Jul 14, 2025

Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India

Jul 14, 2025
pulisher
Jul 06, 2025

Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks

Jul 06, 2025
pulisher
Jul 04, 2025

Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 01, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 01, 2025
pulisher
Jun 27, 2025

Analyst Coverage Updates - The Globe and Mail

Jun 27, 2025
pulisher
Jun 24, 2025

Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks

Jun 24, 2025
pulisher
Jun 12, 2025

Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize

Jun 09, 2025
pulisher
Jun 04, 2025

Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks

Jun 04, 2025
pulisher
Jun 03, 2025

Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks

Jun 02, 2025
pulisher
May 14, 2025

Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks

May 14, 2025
pulisher
Apr 29, 2025

Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks

Apr 29, 2025
pulisher
Apr 22, 2025

Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks

Apr 08, 2025
pulisher
Mar 27, 2025

Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks

Mar 24, 2025
pulisher
Mar 18, 2025

Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 01, 2025

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN

Mar 01, 2025
pulisher
Feb 24, 2025

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 24, 2025
pulisher
Feb 11, 2025

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily

Feb 10, 2025

Abivax Adr (ABVX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
大文字化:     |  ボリューム (24 時間):